Vaccine against Covid-19
Copyright© Ute Grabowsky/photothek.net
Cooperation outside the core areas: Health Developing vaccine production capacity
The BMZ is providing a 50 million euro package to support South African partners' efforts to develop local production capacity. Funding is provided for optimising vaccine logistics and cold chain management, and for strengthening regulatory and certification organisations. Training activities and support for research are intended to enable South Africa to also develop other vaccines.
Moreover, the Deutsche Investitions- und Entwicklungsgesellschaft (DEG) has contributed to a financing package for Aspen, a South African company that has produced the Johnson & Johnson vector vaccine under licence since April 2021. This multi-donor funding will enable the company to increase production from 300 million to 600 million doses a year.
As at: 27/12/2022